In this light, the N-hydroxy urea atreleuton (VA-2291, 3b, Figure 1) is currently in clinical trials for the treatment of cardiovascular diseases and vascular inflammation7, while the orally active hydroxamate containing a sulphonamide linker (4, Figure 1) has been reported as a 5-LO inhibitor with potential use in 5-LO mediated cancers.3 This evidence concerns the gene ALOX5 and cancer.